Short answer
AtriCure, Inc. (ATRC) filed an 8-K current report with the SEC on July 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results release for quarter ended June 30, 2026.
AtriCure, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results release for quarter ended June 30, 2026
- Conference call scheduled July 23, 2026 at 4:30 p.m. Eastern Time
- Detailed financial results furnished in Exhibit 99.1 for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $153.6M, up 12.8% YoY, led by U.S. pain management and appendage management products
- GAAP net income $9.0M versus $6.2M loss, with diluted EPS $0.18 versus $(0.13)
- Adjusted EBITDA $27.3M, up 78%, while gross margin expanded 269 basis points to 77.2%
- Cash generation $21.6M supports liquidity, with cash and equivalents of $167.8M at June 30
- 2026 guidance maintained at $602M-$610M revenue and $85M-$89M adjusted EBITDA
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AtriCure, Inc. 8-K filings
Get the next ATRC 8-K as it lands
Follow ATRC for push alerts, or ask the research agent what this filing means.